Generic Name: palbociclib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Pfizer

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Ibrance is a CDK4/6 kinase inhibitor approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with hormone therapy.

General Info

Ibrance inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which play a role in cell growth and division. Blocking these kinases interferes with breast cancer growth.

The PALOMA-2 trial showed that Ibrance plus the aromatase inhibitor Femara (letrozole) improved progression-free survival in postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer who had not yet received treatment for advanced disease. PALOMA-3 showed that Ibrance plus Faslodex (fulvestrant) extended progression-free survival in pre- or postmenopausal women with hormone receptor-positive, HER2-negative breast cancer that progressed during or after hormone therapy. It was first approved in 2015.


Dosing Info:

Ibrance is taken as a capsule once daily with food. It is usually taken for three weeks followed by a week off.

Side Effects

Common side effects include fatigue, nausea and vomiting, diarrhea, mouth sores, skin rash, hair loss and decreased appetite. Ibrance can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Ibrance should not be used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: December 4, 2018